Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables (2017 - 2026)

Neurocrine Biosciences filings provide 16 years of Receivables readings, the most recent being $707.3 million for Q4 2025.

  • On a quarterly basis, Receivables rose 43.32% to $707.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $707.3 million, a 43.32% increase, with the full-year FY2025 number at $707.3 million, up 43.32% from a year prior.
  • Receivables hit $707.3 million in Q4 2025 for Neurocrine Biosciences, down from $728.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $728.0 million in Q3 2025 to a low of $151.0 million in Q1 2021.
  • Median Receivables over the past 5 years was $411.0 million (2023), compared with a mean of $399.7 million.
  • Biggest five-year swings in Receivables: dropped 1.5% in 2021 and later surged 88.97% in 2022.
  • Neurocrine Biosciences' Receivables stood at $187.7 million in 2021, then soared by 88.97% to $354.7 million in 2022, then increased by 27.01% to $450.5 million in 2023, then grew by 9.54% to $493.5 million in 2024, then soared by 43.32% to $707.3 million in 2025.
  • The last three reported values for Receivables were $707.3 million (Q4 2025), $728.0 million (Q3 2025), and $595.7 million (Q2 2025) per Business Quant data.